✦ LIBER ✦

Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines

✍ Scribed by Ma, Brigette B. Y.; Lui, Vivian W. Y.; Hui, Connie W. C.; Lau, Cecilia P. Y.; Wong, Chi-Hang; Hui, Edwin P.; Ng, Margaret H.; Tsao, S. W.; Li, Yan; Chan, Anthony T. C.

Book ID: 121637907
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 691 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-012-9896-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Testing of the Akt/PKB inhibitor MK-2206

Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program

✍ Richard Gorlick; John M. Maris; Peter J. Houghton; Richard Lock; Hernan Carol; R 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 426 KB

Targeted AKT Inhibition by MK2206 in Hep

Targeted AKT Inhibition by MK2206 in Hepatocellular Carcinoma Reduces Cellular Proliferation Via Induction of Apoptosis and Cell Cycle Arrest

✍ Wilson, J.M.; Kunnimalaiyaan, S.; Kunnimalaiyaan, M.; Gamblin, T. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 167 KB

Preclinical evaluation of dasatinib, a p

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines

✍ Alex J Eustace; John Crown; Martin Clynes; Norma O'Donovan 📂 Article 📅 2008 🏛 BioMed Central 🌐 English ⚖ 503 KB

A phase 1 study evaluating the combinati

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

✍ Hudis, Clifford; Swanton, Charles; Janjigian, Yelena Y; Lee, Ray; Sutherland, St 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 622 KB

Preclinical evaluation of the PI3K-mTOR

Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma

✍ Wong, Chi Hang; Loong, Herbert H.; Hui, Connie W. C.; Lau, Cecilia P. Y.; Hui, E 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 440 KB

Preclinical testing of the Akt inhibitor

Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia

✍ Camilla Evangelisti; Francesca Ricci; Pierluigi Tazzari; Francesca Chiarini; Mic 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 659 KB

## Abstract Over the past 20 years, survival rates of T‐cell acute lymphoblastic leukemia (T‐ALL) patients have improved, mainly because of advances in polychemotherapy protocols. Despite these improvements, we still need novel and less toxic treatment strategies targeting aberrantly activated sign